Mentari Therapeutics, Inc., formerly known as InMed Pharmaceuticals Inc., filed a Form 8-K current report on November 9, 2026, announcing the completion of its previously disclosed merger with Mentari Therapeutics, Inc., a Delaware corporation.

Key Highlights

  • Merger completed: Mentari Therapeutics, Inc. disclosed the completion of its merger with Mentari Therapeutics, Inc., a Delaware corporation, as reported on November 9, 2026.
  • Name change: The registrant was formerly known as InMed Pharmaceuticals Inc. and has adopted the name Mentari Therapeutics, Inc.
  • New ticker symbol: The company's common stock, par value $0.0001 per share, is listed on The Nasdaq Capital Market under the trading symbol MTRI.
  • Registered in Nevada: The registrant is incorporated in Nevada, with principal executive offices now located in Waltham, Massachusetts.
  • Press release furnished: A press release announcing the merger completion was furnished as Exhibit 99.1 to the filing.
  • Signed by General Counsel: The filing was signed by Jerad G. Seurer, General Counsel and Corporate Secretary of Mentari Therapeutics, Inc.

Merger Completion and Corporate Identity Change at Mentari Therapeutics

According to the filing, Mentari Therapeutics, Inc. - formerly known as InMed Pharmaceuticals Inc. - reported the completion of a previously disclosed merger with Mentari Therapeutics, Inc., a Delaware corporation. The event was reported under Item 7.01 Regulation FD Disclosure of the Form 8-K, with the accompanying press release furnished as Exhibit 99.1 rather than filed, meaning, as the company disclosed, it "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

The company's registered securities table in the filing identifies the registrant's common stock, par value $0.0001 per share, as trading under the symbol MTRI on NASDAQ:MTRI. The filing notes that the former name of the registrant was InMed Pharmaceuticals Inc., with a prior principal address in Vancouver, British Columbia. The registrant's current principal executive offices are listed as 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453. The company is incorporated in Nevada and carries Commission File Number 001-39685.

The filing was executed on November 9, 2026, by Jerad G. Seurer in his capacity as General Counsel and Corporate Secretary. The registrant is not classified as an emerging growth company under the applicable definitions referenced in the filing. No financial statements accompanied this current report; the exhibits consist of the press release and a Cover Page Interactive Data File embedded within the Inline XBRL document.

What Was Disclosed

Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., filed an 8-K on November 9, 2026, disclosing the completion of its merger with a Delaware corporation of the same name, a change in its principal address to Waltham, Massachusetts, and the adoption of the MTRI trading symbol on the Nasdaq Capital Market.